ArticleBreast cancer (Tokyo, Japan)2020

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.

Weiting Liao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.